CLINICAL_TRIALS
trial_result
· 2014-10-21
Clinical Trial Update: Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) [Phase 3]
Summary
EPIC is a Phase 3 trial evaluating ponatinib as initial therapy in newly diagnosed chronic myeloid leukemia; the study was terminated, with results posted in 20…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ariad Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2014-10-21